Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204171) titled 'Phase 1 Study of Oral MG001' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: National Institute on Drug Abuse (NIDA)
Condition:
Safety and Tolerability in Healthy Subjects
Intervention:
Drug: mitragynine
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: February 2026
Target Sample Size: 32
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/stud...